

Resource Summary Report

Generated by [RRID](#) on Jul 28, 2026

APC anti-human CD19

RRID:AB_2564127

Type: Antibody

Proper Citation

BioLegend Cat# 363005, RRID:AB_2564127

Antibody Information

URL: http://antibodyregistry.org/AB_2564127

Proper Citation: BioLegend Cat# 363005, RRID:AB_2564127

Target Antigen: CD19

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: APC anti-human CD19

Description: This monoclonal targets CD19

Target Organism: human

Clone ID: Clone SJ25C1

Antibody ID: AB_2564127

Vendor: BioLegend

Catalog Number: 363005

Alternative Catalog Numbers: 363006

Record Creation Time: 20250820T020203+0000

Record Last Update: 20250820T123056+0000

Ratings and Alerts

No rating or validation information has been found for APC anti-human CD19.

No alerts have been found for APC anti-human CD19.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 5 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Li YR, et al. (2025) Protocol to profile tumor and microenvironment from ovarian cancer patient samples and evaluate cell-based therapy using in vitro killing assays. STAR protocols, 6(2), 103742.

Li YR, et al. (2025) Overcoming ovarian cancer resistance and evasion to CAR-T cell therapy by harnessing allogeneic CAR-NKT cells. Med (New York, N.Y.), 100804.

Fang Y, et al. (2025) Protocol to generate allorejection-resistant universal CAR-NKT cells and evaluate their efficacy, mechanism of action, safety, and immunogenicity. STAR protocols, 6(2), 103810.

Li YR, et al. (2023) Profiling ovarian cancer tumor and microenvironment during disease progression for cell-based immunotherapy design. iScience, 26(10), 107952.

Li YR, et al. (2022) Off-the-shelf third-party HSC-engineered iNKT cells for ameliorating GvHD while preserving GvL effect in the treatment of blood cancers. iScience, 25(9), 104859.